Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H56:IC31 phase 2 trial for prevention of recurrent tuberculosis after successful treatment
PACTR201808711101850Phase 2Completed
- Sponsor
- IAVI
- Start
- Apr 2019
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in Tuberculosis (TB) comparing H56:IC31 with Placebo (2 arms). Started Apr 2019; status: completed.
02
Drugs
AERAS-456
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on PACTR201808711101850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201808711101850.